Glucagon-Like Peptide-1 Receptor Agonists: all 1,407 studies that test it

Page 14 of 15. Open to participants first (306), then studies with results posted, then the rest; newest registration first within each.

• Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy VolunteersCompletedNCT01507337Phase 1
• Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 DiabetesCompletedNCT01507311Phase 1
• Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 DiabetesCompletedNCT01507285Phase 1
• Safety and Tolerability of Liraglutide in Healthy Male VolunteersCompletedNCT01507272Phase 1
• Effects of the GLP-1 Exenatide on Satiety in Lean and Obese WomenCompletedNCT01501084Phase 1
• Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 DiabetesCompletedNCT01499108Phase 4
• Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic PatientsCompletedNCT01473147Not applicable
• The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes MellitusCompletedNCT01472640Not applicable
• Identifying Potential Effects of Liraglutide on Degenerative ChangesCompletedNCT01469351Not applicable
• The Effect of Glucagon Like Peptide (GLP)-1 in PsoriasisCompletedNCT01460069Not applicable
• A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 DiabetesWithdrawnNCT01455922Phase 3
• A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesWithdrawnNCT01455909Phase 3
• A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650CompletedNCT01455896Phase 3
• A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 DiabetesWithdrawnNCT01455883Phase 3
• A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesCompletedNCT01455870Phase 3
• A Study to Evaluate ITCA 650 for the Treatment of Type 2 DiabetesCompletedNCT01455857Phase 3
• GLP-1 Receptors in Normal Skin and Skin From Patients With PsoriasisStatus unknownNCT01451905Not applicable
• Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 DiabetesStatus unknownNCT01435980Phase 4
• Liraglutide and Heart Failure in Type 2 DiabetesCompletedNCT01425580Phase 2
• Albiglutide Thorough ECG Study in Healthy VolunteersCompletedNCT01406262Phase 1
• Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 DiabetesCompletedNCT01399645Phase 2
• Liraglutide Treatment to Patients With Severe Renal InsufficiencyCompletedNCT01394341Phase 4
• Liraglutide and Insulin Therapy in Patients With Type 2 DiabetesStatus unknownNCT01392898Not applicable
• Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary BypassCompletedNCT01373216Phase 3
• GLP-1: Acute Effects on Kidney Function in Healthy MenCompletedNCT01333163Not applicable
• Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 DiabetesCompletedNCT01324505Phase 1
• Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy SubjectsCompletedNCT01319240Phase 1
• GLP Analogs for Diabetes in Wolfram Syndrome PatientsWithdrawnNCT01302327Not applicable
• The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and DiabetesCompletedNCT01281228Not applicable
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male SubjectsCompletedNCT01272973Phase 1
• LIraglutide and Beta-cell RepAir (LIBRA) StudyCompletedNCT01270789Phase 3
• The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic PatientsStatus unknownNCT01270191Phase 4
• Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)Status unknownNCT01254123Phase 3
• Liraglutide Efficacy and Action in Non-Alcoholic SteatohepatitisCompletedNCT01237119Phase 2
• Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes MellitusCompletedNCT01235819Phase 4
• Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT01208649Phase 4
• Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes MellitusCompletedNCT01208012Phase 4
• Exendin-4 as a Treatment for Parkinson's Disease - Pilot StudyStatus unknownNCT01174810Phase 2
• A Drug Interaction Study With Albiglutide and WarfarinCompletedNCT01147731Phase 1
• A Drug Interaction Study of Albiglutide and DigoxinCompletedNCT01147718Phase 1
• A Drug Interaction Study of Simvastatin and AlbiglutideCompletedNCT01147692Phase 1
• Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 DiabetesStatus unknownNCT01140893Phase 2/3
• An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .CompletedNCT01077505Phase 1
• Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes TreatmentCompletedNCT01076842Phase 4
• Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in HumansCompletedNCT01056549Not applicable
• Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its MechanismsCompletedNCT01046721Not applicable
• A Two Part Trial Investigating the Safety of NN9924 in Healthy Male SubjectsCompletedNCT01037582Phase 1
• Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 DiabetesCompletedNCT00993720Phase 2/3
• A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 DiabeticsCompletedNCT00993304Phase 1
• Safety and Tolerability of NN9068 in Healthy Male VolunteersCompletedNCT00983021Phase 1
• A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese VolunteersCompletedNCT00978393Phase 1
• Effects of Exenatide on Postprandial Hyperlipidemia and InflammationCompletedNCT00974272Phase 4
• A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) ExenatideCompletedNCT00964262Phase 1
• The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 DiabetesCompletedNCT00950677Phase 4
• Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 DiabetesCompletedNCT00948168Phase 4
• Safety of Liraglutide in Pediatric Patients With Type 2 DiabetesCompletedNCT00943501Phase 1
• A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.CompletedNCT00938158Phase 1
• Examination of the Effects of Liraglutide on the Mode of Action of Insulin DetemirCompletedNCT00873223Phase 1
• The Effects of Exenatide After Gastric RestrictionStatus unknownNCT00872378Phase 2/3
• Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian SubjectsCompletedNCT00851773Phase 1
• The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young AdultsWithdrawnNCT00845559Phase 4
• Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCICompletedNCT00835848Phase 4
• Effect of Renal Impairment on the Pharmacokinetics of NN9535CompletedNCT00833716Phase 1
• A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male SubjectsCompletedNCT00813020Phase 1
• Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart FailureCompletedNCT00766857Phase 4
• To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or PlaceboCompletedNCT00761540Phase 1
• The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PETCompletedNCT00747968Phase 2/3
• PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatideCompletedNCT00744224Not applicable
• Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy SubjectsCompletedNCT00672399Phase 1
• A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes MellitusCompletedNCT00642538Phase 1
• A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 DiabetesCompletedNCT00612794Phase 1
• Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesWithdrawnNCT00572689Phase 4
• Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi SyndromeCompletedNCT00551343Not applicable
• Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.CompletedNCT00537719Phase 1
• Clinical Assessment of GSK716155 for Type 2 Diabetes MellitusCompletedNCT00530309Phase 1
• A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes MellitusCompletedNCT00477581Phase 4
• A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult MalesCompletedNCT00475371Phase 1
• Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy VolunteersCompletedNCT00394030Phase 1
• A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 DiabetesCompletedNCT00382239Phase 2
• Safety and Efficacy of Exenatide as MonotherapyCompletedNCT00381342Phase 3
• Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 DiabetesCompletedNCT00359879Phase 3
• In-patient Study With GSK716155 In Patients With Type 2 Diabetes MellitusCompletedNCT00354536Phase 2
• Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesCompletedNCT00333151Phase 3
• Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesCompletedNCT00331851Phase 3
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and MetforminCompletedNCT00324363Phase 3
• Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesCompletedNCT00318422Phase 3
• Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.CompletedNCT00313001Phase 3
• GLP-1 Infusion and Long-Time FastingCompletedNCT00285896Not applicable
• In-patient Study in Patients With Type 2 Diabetes MellitusCompletedNCT00259896Phase 1
• The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy FemalesCompletedNCT00254800Phase 1
• Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 DiabetesCompletedNCT00241423Phase 2
• Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 DiabetesCompletedNCT00154414Phase 2
• Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesCompletedNCT00154401Phase 2
• Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 DiabetesCompletedNCT00111540Phase 3
• Study Examining Exenatide Long-Acting Release in Subjects With Type 2 DiabetesCompletedNCT00103935Phase 2
• Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate TherapyCompletedNCT00099619Phase 3
• PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart FailureCompletedNCT00099580Phase 2
• Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic AgentsCompletedNCT00099333Phase 2
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and MetforminCompletedNCT00099320Phase 3
• Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes MellitusCompletedNCT00085969Phase 2

← Glucagon-Like Peptide-1 Receptor Agonists overview